These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20560974)

  • 1. 5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer.
    Uemura M; Honma S; Chung S; Takata R; Furihata M; Nishimura K; Nonomura N; Nasu Y; Miki T; Shuin T; Fujioka T; Okuyama A; Nakamura Y; Nakagawa H
    Cancer Sci; 2010 Aug; 101(8):1897-904. PubMed ID: 20560974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.
    Mostaghel EA
    Int J Biol Sci; 2014; 10(6):602-13. PubMed ID: 24948873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?
    Storbeck KH; Bloem LM; Africander D; Schloms L; Swart P; Swart AC
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):135-46. PubMed ID: 23856005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer.
    Audet-Walsh É; Yee T; Tam IS; Giguère V
    Endocrinology; 2017 Apr; 158(4):1015-1021. PubMed ID: 28324044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5α-reductase type 3 enzyme in benign and malignant prostate.
    Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
    Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer.
    Campbell TJ; Tindall DJ; Figg WD
    Cancer Biol Ther; 2012 Mar; 13(5):237-8. PubMed ID: 22336886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues.
    Dai C; Chung YM; Kovac E; Zhu Z; Li J; Magi-Galluzzi C; Stephenson AJ; Klein EA; Sharifi N
    Clin Cancer Res; 2017 Oct; 23(20):6351-6362. PubMed ID: 28733443
    [No Abstract]   [Full Text] [Related]  

  • 8. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.
    Sharifi N
    J Investig Med; 2012 Feb; 60(2):504-7. PubMed ID: 22064602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
    Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
    J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
    Mostaghel EA; Morgan A; Zhang X; Marck BT; Xia J; Hunter-Merrill R; Gulati R; Plymate S; Vessella RL; Corey E; Higano CS; Matsumoto AM; Montgomery RB; Nelson PS
    PLoS One; 2014; 9(10):e111545. PubMed ID: 25356728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
    Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
    Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.
    Chang KH; Li R; Papari-Zareei M; Watumull L; Zhao YD; Auchus RJ; Sharifi N
    Proc Natl Acad Sci U S A; 2011 Aug; 108(33):13728-33. PubMed ID: 21795608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11β-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione.
    Swart AC; Schloms L; Storbeck KH; Bloem LM; Toit Td; Quanson JL; Rainey WE; Swart P
    J Steroid Biochem Mol Biol; 2013 Nov; 138():132-42. PubMed ID: 23685396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
    Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
    Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
    du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
    J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the androgen receptor pathway in prostate cancer.
    Chen Y; Sawyers CL; Scher HI
    Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.